Treatment Satisfaction with Tenapanor: Real-World Survey of Patients with End-Stage Renal Disease and Hyperphosphatemia.

Purpose: Tenapanor (XPHOZAH), approved by the US FDA in October 2023, is indicated to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to or are intolerant of any dose of phosphate binders. Unlike phosphate binders, tenapanor inhibits phosphate absorption by reducing permeability through the paracellular pathway. We report results of a real-world survey on patient perspectives of serum phosphate management while receiving tenapanor for hyperphosphatemia. Patients and Methods: Survey invites were distributed via the ArdelyxAssist patient assistance program and survey responses were coupled to pharmacy dispensing data. Eligible participants were patients with hyperphosphatemia on maintenance dialysis receiving tenapanor for at least 7 weeks, last dispensed no more than 12 weeks before the survey. Results: Among 163 respondents (60% male, median age 60), the median duration of tenapanor use was 133 days. Many patients were unaware of their current serum phosphate levels (39%) or changes since starting tenapanor (57%). Excluding these patients, 74% reported good/very good serum phosphate control and 63% noted improved control. Longer duration of tenapanor use correlated with increased awareness of ( Conclusion: The survey results suggest that patients experience positive outcomes with real-world use of tenapanor, including improved bowel movements, serum phosphate control, and reduced pill burden. These findings highlight the ability of tenapanor to address unmet needs in hyperphosphatemia management.